• As new consumer hardware and software capabilities have bumped up against medicine over the last few years, consumers and manufacturers alike have struggled with identifying the line between “wellness” products such as earbuds that can also amplify and clarify surrounding speakers’ voices and regulated medical devices such as conventional hearing aids. • On January 6, 2026, the U.S. • Food and Drug Administration issued new guidance documents clarifying how it interprets existing law for the review of wearable and AI-assisted devices. • The first document, for general wellness, specifies that the FDA will interpret noninvasive sensors such as sleep trackers or heart rate monitors as low-risk wellness devices while treating invasive devices under conventional regulations. • The other document defines how the FDA will exempt clinical decision support tools from medical device regulations, limiting such software to analyzing existing data rather than extracting data from sensors, and requiring them to enable independent review of their recommendations. • The documents do not rewrite any statutes, but they refine interpretation of existing law, compared to the 2019 and 2022 documents they replace.

Article Summaries:

  • Summary

On January 6 2026 the FDA released two guidance documents that refine how existing law applies to wearable and AI‑assisted devices. The first clarifies that non‑invasive sensors (e.g., sleep trackers, heart‑rate monitors) are treated as low‑risk wellness products, while invasive devices remain under conventional medical‑device regulation. The second exempts clinical‑decision‑support software that only analyzes pre‑existing data and permits independent review of its recommendations, even if it offers a single option. The guidance also distinguishes “medical information” from continuous signal‑measuring systems, giving concrete examples such as continuous glucose monitors versus lab glucose results. Accuracy requirements remain unchanged, and the FDA signals a more nuanced, less restrictive stance compared to earlier guidance.

  • The U.S. Food and Drug Administration released two guidance documents on January 6, 2026 that refine how it interprets existing law for wearable and AI‑assisted devices. The first clarifies that non‑invasive sensors such as sleep trackers and heart‑rate monitors are low‑risk wellness products, while invasive devices remain under conventional medical‑device regulations. The second exempts certain clinical decision‑support tools from regulation if they analyze existing data rather than extract new sensor data and must allow independent review of their recommendations. The guidance also defines “signal‑measuring” systems and distinguishes medical information from physiological signals, providing concrete examples. These updates offer clearer regulatory boundaries for consumer electronics that overlap with medicine.

Sources: